肺癌患者不同治疗下健康效用值的动态变化:7年随访
本研究基于2011至2017年一家医疗中心的真实世界数据,对1715例肺癌患者进行重复测量,共收集6762次生活质量评估。研究描绘了诊断及治疗后生活质量效用值的轨迹,发现二线靶向治疗在多个时间段效用值高于化疗,混合模型控制混杂因素后靶向治疗在3至6个月及6个月以上仍显示更高效用值。
要点
- 晚期和老年肺癌患者健康效用值更低。
- 二线靶向治疗在0至3个月、3至6个月及6个月以上效用值高于化疗。
- 混合模型控制混杂后二线靶向治疗在3至6个月及6个月以上效用值仍更高。
核心结论
- 靶向治疗为患者提供的健康效用值高于化疗。
- 纵向轨迹开发有助于预测生活质量变化并改善肺癌幸存者照护。
研究设计与样本
- 2011至2017年在一家医疗中心邀请所有就诊肺癌患者填写EQ-5D和WHOQOL-BREF问卷。
- 共纳入1715例患者,获得6762次生活质量测量。
- 使用核平滑法描绘诊断和治疗后生活质量效用值轨迹。
- 构建线性混合模型预测各时间段健康效用,并用WHOQOL-BREF领域评分进行交叉验证。
主要发现
- 晚期和老年患者效用值更低。
- 二线靶向治疗在0至3个月、3至6个月和6个月以上效用值分别为0.89、0.90和0.88,高于化疗的0.81、0.85和0.80。
- 混合模型控制体力状态差和疾病进展等混杂后,二线化疗健康效用与准基线相似。
- 二线靶向治疗在3至6个月(β=0.07,p=0.010)和6个月以上(β=0.07,p<0.001)效用值更高。
- 效用值与生理和心理领域评分具有收敛效度。
临床怎么用
- 在肺癌患者治疗选择中可参考不同治疗对健康效用值的影响。
- 纵向效用轨迹有助于预测生活质量变化并指导幸存者照护。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: This study aimed to estimate the utility values of all subtypes of lung cancer. The trajectories after different kinds of treatments and their major determinants were explored on the basis of real-world data and repeated measurements. METHODS: From 2011 to 2017, all patients with lung cancer who visited a medical center were invited to fill out the EuroQol Five-Dimension and WHO Quality of Life-Brief questionnaires at each visit. Utility values of quality of life (QoL) after diagnosis and treatments were depicted using a kernel smoothing method. We constructed linear mixed models to predict health utility in each time period and cross-validated them with domain scores of the WHO Quality of Life-Brief. RESULTS: A total of 1715 patients were enrolled, with 6762 QoL measurements. Utility values were lower in patients with advanced-stage disease and older patients. Patients receiving second-line targeted therapy showed higher utility values at 0 to 3 months, 3 to 6 months, and 6 months and beyond (0.89, 0.90, and 0.88, respectively) than did those undergoing chemotherapy (0.81, 0.85, and 0.80, respectively). After using mixed models to control confounders, including poor performance status and disease progression, patients receiving second-line chemotherapy showed health utility similar to that at quasi-baseline, whereas utility values related to second-line targeted therapy were higher at 3 to 6 months and 6 months and beyond (β = 0.07, p = 0.010 and β = 0.07, p < 0.001, respectively). There was convergent validity between the utility values and scores of the physical and psychological domains. CONCLUSION: Targeted therapy provided treated patients with a higher health utility value than was provided to those treated with chemotherapy. Development of the longitudinal trajectory may help predict changes in QoL and improve the care of lung cancer survivors.
引用
- Yang SC, Kuo CW, Lai WW, et al. Dynamic Changes of Health Utility in Lung Cancer Patients Receiving Different Treatments: A 7-Year Follow-up. J Thorac Oncol. 2019. PMID: 31352073. doi:10.1016/j.jtho.2019.07.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。